Immupharma PLC Appointment of Nominated Adviser (5484K)

TIDMIMM

RNS Number : 5484K

Immupharma PLC

17 December 2018

ImmuPharma PLC

("ImmuPharma" or the "Company")

APPOINTMENT OF NOMINATED ADVISOR

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company is pleased to announce the appointment of SPARK Advisory Partners Limited ("SPARK") as the Company's Nominated Advisor ("NOMAD"), with immediate effect.

Commenting on the appointment, ImmuPharma's Chairman, Tim McCarthy, said:

"I am delighted to announce the appointment of SPARK as the Company's NOMAD. We look forward to working with the team going forward, alongside our joint brokers, Stanford Capital Partners and SI Capital."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")

 
 
  For further information please contact: 
   ImmuPharma plc (www.immupharma.com)                             + 44 (0) 207 152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor Relations                       + 44 (0) 7721 413496 
   SPARK Advisory Partners Limited (NOMAD) 
    Neil Baldwin                                                   +44 (0) 203 368 8974 
    Vassil Kirtchev 
 
    Stanford Capital Partners (Joint Broker) 
    Patrick Claridge, John Howes                                   +44 (0) 203 815 8880 
 
    SI Capital (Joint Broker) 
    Nick Emerson                                                   +44 (0) 1483 413500 
 
    About SPARK Advisory Partners Limited 
 
    SPARK Advisory Partners was established in January 2012 by 
    its 
    founding partners to provide product independent corporate 
    finance 
    advice to mid-market companies, owner managers and 
    shareholders. 
    SPARK is owned by its partners who have worked together for 
    many years. The team has a broad cross section of skills and 
    transaction experience, encompassing M&A, private equity, 
    public 
    capital raisings and debt advisory services. For more 
    information 
    go to: www.sparkadvisorypartners.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

APPBBBDDCBBBGIS

(END) Dow Jones Newswires

December 17, 2018 02:01 ET (07:01 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From May 2024 to Jun 2024